Therefore, the FAM83H-SCRIB-β-catenin pathway might be a novel therapeutic target for the poor prognostic subgroups of gastric cancer, which express high levels of FAM83H and SCRIB. The gene discussed is SCRIB; the disease is gastric cancer.